ALXN-2350

N/A

Report date: 2026/03/06 20:02:51

Base Information

Drug NameALXN-2350
Drug Alias NameALXN2350ALXN-2350
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionBAG3 gene transference
TargetsBAG family molecular chaperone regulator 3
Therapy Area/IndicationsCardiomyopathy, Dilated
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlexion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlexion Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCardiomyopathy, Dilated
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A